Studies Highlight New Therapies and Immunotherapies in Blood Cancer Treatment
The field of blood cancer treatment is witnessing a paradigm shift with the emergence of targeted therapies and immunotherapies, offering promising alternatives to traditional chemotherapy. Recent studies presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition have shed light on these innovative approaches, showcasing their potential to improve patient outcomes and quality of life.
Combination Therapies for Acute Myeloid Leukemia (AML):
- A study comparing azacitidine and venetoclax to conventional induction chemotherapy in newly diagnosed, fit adults with AML showed superior event-free survival and higher response rates with the combination regimen. This approach is particularly beneficial for patients with intermediate-to-high-risk disease, reducing hospitalization and symptom burden.
Chemotherapy-Free Approach for Follicular Lymphoma:
- A combination of epcoritamab, a bispecific antibody, and rituximab and lenalidomide, an immunotherapeutic combination, demonstrated robust and lasting responses in patients with relapsed or refractory follicular lymphoma. This chemo-free approach is administered on an outpatient basis, offering a promising alternative to chemotherapy.
Tyrosine Kinase Inhibitors (TKIs) in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL):
- Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, showed non-inferiority to the older covalent inhibitor ibrutinib in a phase III study. This finding suggests that pirtobrutinib is a viable option for both treatment-naive and relapsed/refractory patients with CLL and SLL.
Chemotherapy-Free Treatment for Ph+ Acute Lymphoblastic Leukemia (ALL):
- A combination of ponatinib, a TKI, and blinatumomab, an immunotherapy, outperformed a TKI plus chemotherapy regimen in a phase III trial. This chemo-free approach demonstrated higher event-free survival and complete remission rates, offering a promising new standard of care for Ph+ ALL patients.
